Nindalieva 150mg capsule

Most side effects of Nindalieva 150mg Capsule do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.

Common side effects include:

• Abdominal pain
  
• Diarrhea
  
• Nausea
  
• Vomiting
  
• Abnormal liver function tests
  
• Loss of appetite
  
• Headache
  
• Weight loss
  
• High blood pressure
  

• Doctor determines the exact dose and duration with Nindalieva 150mg Capsule as per the overall health condition of the patient.
• The typical recommended dose of the capsule is twice daily.
• This capsule should be taken with food, but at the fix time every day to get effective results.
• Don't miss a dose or overdose on the medicine.
• Swallow it as a whole with a glass of water and do not crush, chew, or open it.

• Nindalieva 150mg Capsule is an anticancer medicine that contains Nintedanib Soft Gelatin.
• This medicine works by inhibiting the pathways responsible for fibrosis and reducing the scarring & swelling in the lungs results in better breath.
• It also blocks the action of abnormal protein to stop or slow the spread of cancer cells.
  

• Atanelishvili, I., Akter, T., Noguchi, A., Vuyiv, O., Wollin, L., Silver, R. M., & Bogatkevich, G. S. (2019). Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease. Clin Exp Rheumatol, 37(Suppl 119), S115-24.
  
• Singh, S., & Wairkar, S. (2024). Revolutionizing the treatment of idiopathic pulmonary fibrosis: from conventional therapies to advanced drug delivery systems. AAPS PharmSciTech, 25(4), 78.
  
• Wan, Q., Li, D., Shang, S., Wu, H., Chen, F., & Li, Q. (2025). Novel synergistic therapeutic approach in idiopathic pulmonary fibrosis: Combining the antifibrotic nintedanib with the anti-inflammatory baricitinib. Pulmonary Pharmacology & Therapeutics, 89, 102346.
  
• Yun, C. X., Huan, M. L., Zhu, X., Wan, Y. H., Zou, J. B., & Zhang, B. L. (2024). Construction of the pulmonary bio-adhesive delivery system of nintedanib nanocrystalline for effective treatment of pulmonary fibrosis. International Journal of Pharmaceutics, 660, 124302.
  
• Thakkar, D., Singh, S., & Wairkar, S. (2024). Advanced delivery strategies of nintedanib for lung disorders and beyond: A comprehensive review. AAPS PharmSciTech, 25(6), 150.
  
• Trivedi, M. D., Dubal, G., & Vora, P. A. (2023). Nintedanib as the First Treatment for Group of Progressive Interstitial Lung Diseases: A Review of Patent Literature. Recent Advances in Inflammation & Allergy Drug Discovery, 17(2), 96-109.